Palmitoylethanolamide (PEA) — Safety, Research, Risks & Legal Status

Not medical advice. Palmitoylethanolamide (PEA) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	PEA, N-palmitoylethanolamine, N-(2-hydroxyethyl)hexadecanamide, palmidrol, Normast, PeaPure, Levagen, Levagen+, CAS 544-31-0
Category	Supplement
Compound class	Endogenous N-acylethanolamine fatty-acid amide (ALIAmide)
Primary molecular target	PPAR-alpha nuclear receptor (does not bind CB1/CB2 directly)
CAS number	544-31-0
US regulatory status	Sold as a dietary supplement (NDI filed ~2014); not an FDA-approved drug
EU status	Marketed as a 'food for special medical purposes' in Italy/Spain since 2008
Main studied use	Chronic and neuropathic pain / inflammation
US legal status	Legal in the US and generally sold as a dietary supplement. A new dietary ingredient (NDI) notification for PEA was filed with the FDA around 2014, but that filing is not FDA "approval" of safety or efficacy, and PEA is not an FDA-approved drug for any indication. Manufacturers are responsible for their own quality control and cannot lawfully make disease-treatment claims. In parts of Europe (notably Italy and Spain since 2008) PEA is marketed not as a supplement but as a "food for special medical purposes" (a regulated but distinct category) under brands such as Normast. It is endogenous to the human body and present in foods like egg yolk, soy lecithin, and milk. This is one of the few compounds in this reference that is a genuine, legally sold supplement rather than a research chemical, but "legal supplement" is not the same as "proven drug."

What is Palmitoylethanolamide (PEA)?

Palmitoylethanolamide is an endogenous fatty-acid amide (an N-acylethanolamine) that the body produces on demand in response to tissue injury and inflammation. It belongs to the ALIAmide class ("autacoid local injury antagonist amides"), lipid signaling molecules that locally down-regulate mast cell activation and neuroinflammation. It is chemically related to the endocannabinoid anandamide but, importantly, does not itself bind the classical cannabinoid receptors CB1 or CB2. It is studied and marketed primarily for chronic and neuropathic pain and inflammation.

How it works

The best-supported mechanism is agonism of the nuclear receptor PPAR-alpha, which suppresses NF-kappaB-driven transcription of pro-inflammatory cytokines; in PPAR-alpha knockout mice PEA loses its anti-inflammatory effect, which is strong evidence this pathway is central. PEA also acts on mast cells and glia to dampen neuroinflammation (the original ALIA concept). It is described as working partly through an "entourage effect": PEA does not bind CB1/CB2 directly, but by competing for and inhibiting the degradative enzymes FAAH and NAAA it can raise levels of anandamide and thereby indirectly enhance endocannabinoid tone. Additional proposed targets include the orphan receptor GPR55 and the TRPV1 ion channel. Note that several of these mechanisms are inferred from cell and animal work; the relative contribution of each in humans is not fully resolved.

Background & history

PEA's structure was characterized on October 20, 1957 by Kuehl and colleagues, who isolated an anti-inflammatory factor from soybean lecithin, egg yolk phospholipid, and peanut meal and identified it as N-palmitoylethanolamide. Interest faded, then was revived in the 1990s largely through the work of Nobel laureate Rita Levi-Montalcini, whose group linked PEA to control of mast-cell-driven inflammation and coined the ALIA framework. From the 1970s onward it was studied (initially in Eastern Europe, partly as an anti-influenza agent) and later developed in Italy as a "food for special medical purposes" for pain. Recognition of PPAR-alpha as its principal molecular target came in the mid-2000s, reframing it from a vaguely "nonspecific" agent into a defined nuclear-receptor agonist.

What the research says

PEA has an unusually deep human literature for a "supplement": it has been evaluated in more than 30 clinical trials totaling several thousand patients since the 1970s, across low back pain and sciatica, carpal tunnel and other nerve-compression syndromes, diabetic and chemotherapy-induced peripheral neuropathy, post-herpetic neuralgia, osteoarthritis, fibromyalgia, dental/menstrual/pelvic pain, and more. Several systematic reviews and meta-analyses report a statistically significant benefit over control for pain reduction and reduced rescue-medication use. The honest caveat is large: these meta-analyses are repeatedly downgraded for very high statistical heterogeneity (I-squared values near 99 percent), suspected publication bias on funnel-plot inspection, small and short trials, and a body of work heavily produced or funded by manufacturers of specific formulations. So the direction of effect is reasonably consistent but the effect size is uncertain and likely overstated by the published record. It is best described as a plausibly modest, well-tolerated adjunct for chronic pain, not a proven first-line analgesic. Neuroprotective, retinal, mood, and antiviral uses are earlier-stage and largely preclinical or exploratory.

Reported effects

Modest reduction in chronic and neuropathic pain intensity reported across multiple trials (effect size uncertain due to heterogeneity)
Reduced need for rescue analgesics in some studies
Anti-inflammatory / anti-neuroinflammatory action via down-modulation of mast cells and glia
Reported improvements in physical functioning and quality-of-life scores in pain populations
Generally well tolerated with a low adverse-event rate in trials
Proposed neuroprotective effects (largely preclinical / early human)
Slow onset: benefits in trials typically emerge over weeks, not acutely

Dosing & administration (informational)

Informational only, not a protocol or recommendation. The doses appearing in the clinical literature most commonly cluster at 300 mg to 1200 mg per day, frequently given as 300 mg or 600 mg twice daily, using micronized or ultra-micronized formulations, typically over a course of weeks. A clear dose-response relationship has not been firmly established across the trial dataset, and onset of benefit is gradual rather than acute. None of this constitutes dosing guidance; anyone considering PEA for a pain or inflammatory condition should discuss it with a qualified clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Considered one of the better-tolerated pain-modulating compounds; across ~2,000+ trial patients no serious drug-attributed adverse events were reported
Reported side effects are uncommon and mild (e.g. transient GI upset, occasional palpitations) and typically self-resolving
Long-term safety beyond trial durations (which are mostly weeks to a few months) is not well characterized
Safety in pregnancy and breastfeeding is not established; conventional guidance is to avoid unless directed by a clinician
As an unregulated-for-purity supplement in the US, actual product identity, dose accuracy, and contamination are quality concerns; third-party testing matters
It is a symptom-modifier being used in people with real pain conditions; using it to self-manage pain can delay appropriate diagnosis and treatment
Not a substitute for evaluation of the underlying cause of neuropathic or inflammatory pain

Drug & supplement interactions

N
o
w
e
l
l
-
d
o
c
u
m
e
n
t
e
d
,
c
l
i
n
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
h
a
v
e
b
e
e
n
r
e
p
o
r
t
e
d
,
a
n
d
P
E
A
i
s
g
e
n
e
r
a
l
l
y
d
e
s
c
r
i
b
e
d
a
s
i
n
t
e
r
a
c
t
i
o
n
-
l
i
g
h
t
.
T
h
a
t
s
a
i
d
,
f
o
r
m
a
l
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
a
r
e
l
i
m
i
t
e
d
,
s
o
t
h
i
s
i
s
m
o
r
e
a
n
a
b
s
e
n
c
e
o
f
e
v
i
d
e
n
c
e
t
h
a
n
p
r
o
v
e
n
s
a
f
e
t
y
.
T
h
e
o
r
e
t
i
c
a
l
c
a
u
t
i
o
n
i
s
r
e
a
s
o
n
a
b
l
e
w
i
t
h
d
r
u
g
s
a
c
t
i
n
g
o
n
t
h
e
s
a
m
e
p
a
t
h
w
a
y
s
i
t
t
o
u
c
h
e
s
:
o
t
h
e
r
a
n
t
i
-
i
n
f
l
a
m
m
a
t
o
r
i
e
s
,
i
m
m
u
n
o
m
o
d
u
l
a
t
o
r
s
/
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
,
a
n
d
a
g
e
n
t
s
a
f
f
e
c
t
i
n
g
e
n
d
o
c
a
n
n
a
b
i
n
o
i
d
s
i
g
n
a
l
i
n
g
(
i
n
c
l
u
d
i
n
g
c
a
n
n
a
b
i
n
o
i
d
s
)
.
B
e
c
a
u
s
e
i
t
c
a
n
b
e
u
s
e
d
a
l
o
n
g
s
i
d
e
c
o
n
v
e
n
t
i
o
n
a
l
a
n
a
l
g
e
s
i
c
s
,
a
n
y
o
n
e
c
o
m
b
i
n
i
n
g
i
t
w
i
t
h
a
p
r
e
s
c
r
i
b
e
d
p
a
i
n
r
e
g
i
m
e
n
s
h
o
u
l
d
t
e
l
l
t
h
e
i
r
p
r
e
s
c
r
i
b
e
r
r
a
t
h
e
r
t
h
a
n
a
s
s
u
m
e
"
n
a
t
u
r
a
l
"
m
e
a
n
s
i
n
e
r
t
.

Who should avoid it

Pregnant or breastfeeding individuals (safety not established)
Anyone using PEA to self-treat undiagnosed or worsening neuropathic pain instead of seeking medical evaluation
People expecting a fast-acting or potent analgesic effect comparable to prescription pain medication
Those relying on unspecified bulk powder without third-party identity/purity testing
Anyone assuming a 'legal supplement' label guarantees the manufacturer-published efficacy claims

How it is commonly combined

In practice PEA is most often positioned as an add-on to standard pain management rather than a standalone therapy, and some trials pair it with conventional analgesics to reduce rescue-medication use. It is sometimes combined with antioxidants such as luteolin (co-ultramicronized PEA-luteolin formulations exist in the neuroinflammation literature) or with other lipid mediators. It is frequently discussed alongside cannabinoids/CBD because of the shared endocannabinoid interface, though robust human data on such combinations is thin. This site does not endorse any stack; combination use compounds the existing uncertainty about effect size and long-term safety.

Legal & regulatory. Legal in the US and generally sold as a dietary supplement. A new dietary ingredient (NDI) notification for PEA was filed with the FDA around 2014, but that filing is not FDA "approval" of safety or efficacy, and PEA is not an FDA-approved drug for any indication. Manufacturers are responsible for their own quality control and cannot lawfully make disease-treatment claims. In parts of Europe (notably Italy and Spain since 2008) PEA is marketed not as a supplement but as a "food for special medical purposes" (a regulated but distinct category) under brands such as Normast. It is endogenous to the human body and present in foods like egg yolk, soy lecithin, and milk. This is one of the few compounds in this reference that is a genuine, legally sold supplement rather than a research chemical, but "legal supplement" is not the same as "proven drug."

Quality & harm reduction

B
e
c
a
u
s
e
P
E
A
i
s
s
o
l
d
a
s
a
s
u
p
p
l
e
m
e
n
t
i
n
t
h
e
U
S
,
p
u
r
i
t
y
a
n
d
l
a
b
e
l
a
c
c
u
r
a
c
y
a
r
e
n
o
t
f
e
d
e
r
a
l
l
y
v
e
r
i
f
i
e
d
.
L
o
o
k
f
o
r
p
r
o
d
u
c
t
s
s
p
e
c
i
f
y
i
n
g
p
a
r
t
i
c
l
e
e
n
g
i
n
e
e
r
i
n
g
(
m
i
c
r
o
n
i
z
e
d
o
r
u
l
t
r
a
-
m
i
c
r
o
n
i
z
e
d
P
E
A
,
o
r
b
r
a
n
d
e
d
d
i
s
p
e
r
s
i
o
n
s
s
u
c
h
a
s
L
e
v
a
g
e
n
+
)
,
s
i
n
c
e
n
a
t
i
v
e
P
E
A
i
s
p
o
o
r
l
y
w
a
t
e
r
-
s
o
l
u
b
l
e
a
n
d
u
n
f
o
r
m
u
l
a
t
e
d
p
o
w
d
e
r
m
a
y
b
e
l
e
s
s
c
o
n
s
i
s
t
e
n
t
l
y
a
b
s
o
r
b
e
d
.
P
r
e
f
e
r
s
u
p
p
l
i
e
r
s
p
r
o
v
i
d
i
n
g
a
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
a
n
d
t
h
i
r
d
-
p
a
r
t
y
i
d
e
n
t
i
t
y
/
p
u
r
i
t
y
t
e
s
t
i
n
g
(
C
A
S
5
4
4
-
3
1
-
0
)
.
"
U
l
t
r
a
-
m
i
c
r
o
n
i
z
e
d
"
a
n
d
"
m
i
c
r
o
n
i
z
e
d
"
a
r
e
t
h
e
f
o
r
m
s
u
s
e
d
i
n
m
o
s
t
o
f
t
h
e
b
e
t
t
e
r
c
l
i
n
i
c
a
l
t
r
i
a
l
s
;
u
n
s
p
e
c
i
f
i
e
d
b
u
l
k
p
o
w
d
e
r
i
s
a
l
o
w
e
r
-
c
o
n
f
i
d
e
n
c
e
c
h
o
i
c
e
.

Safer, legal alternative we recommend

Plat-Turmeric. For a legal anti-inflammatory support option, our Platinum Turmeric covers a similar goal.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Does PEA actually work for pain?

Multiple meta-analyses show a statistically significant benefit over control for chronic and neuropathic pain, so the direction of effect is fairly consistent. But those analyses are heavily downgraded for extreme heterogeneity (I-squared near 99 percent), likely publication bias, and a literature dominated by manufacturer-linked trials. The realistic read is a modest, adjunctive benefit that is probably overstated by the published record, not a proven potent analgesic.

Is PEA a cannabinoid or related to CBD?

It is chemically related to the endocannabinoid anandamide and interacts with the endocannabinoid system indirectly, but it is not a cannabinoid: it does not bind CB1 or CB2 receptors. Its main action is on the PPAR-alpha nuclear receptor. It is sometimes described as an 'entourage' compound because it can raise anandamide levels by inhibiting the enzymes that break it down.

Is PEA legal and is it FDA approved?

It is legal to sell in the US as a dietary supplement, and a new dietary ingredient notification was filed around 2014. That is not the same as FDA approval: the FDA has not reviewed it for safety or efficacy, it is not an approved drug, and manufacturers cannot lawfully claim it treats disease. In parts of Europe it is regulated instead as a food for special medical purposes.

How much PEA do studies use?

This is informational only and not a recommendation. Trial doses most often fall between 300 and 1200 mg per day, commonly 300 or 600 mg twice daily, using micronized or ultra-micronized forms over several weeks. A clear dose-response has not been firmly established, and effects build gradually. Anyone considering it should consult a clinician rather than self-dose.

Is PEA safe?

Its trial safety record is favorable: across roughly two thousand-plus study participants no serious drug-attributed adverse events were reported, and side effects (mild GI upset, occasional palpitations) are uncommon and transient. The limits are that trials are mostly short, long-term data is sparse, pregnancy/breastfeeding safety is not established, and as an unregulated-for-purity supplement product quality varies.

What forms of PEA are used, and does formulation matter?

Native PEA is poorly water-soluble, so most quality clinical work uses micronized or ultra-micronized particle-engineered forms (or branded dispersions like Levagen+) to improve absorption. Unspecified bulk powder is a lower-confidence choice. Look for a certificate of analysis and third-party identity/purity testing under CAS 544-31-0.

References & further reading

PubMed: palmitoylethanolamide chronic pain systematic review meta-analysis randomized controlled trials
PubMed: PPAR-alpha mediates anti-inflammatory actions of palmitoylethanolamide knockout mice
PubMed: palmitoylethanolamide neuropathic pain nerve compression sciatica carpal tunnel
PubMed: palmitoylethanolamide pharmacokinetics safety efficacy micronized ultramicronized
PubMed: palmitoylethanolamide ALIAmide mast cell Levi-Montalcini history pharmacology